Organisation paid for research Program year 2025 Source: CMS Open Payments

Accellacare - Wilmington

Neither a doctor nor a teaching hospital

Research payments

$363,276

9 payments

Through program year 2025, Accellacare - Wilmington is reported as receiving $363,276 in research payments, across 9 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$75,019	2
2024	Research	$95,664	3
2023	Research	$192,592	4

Breakdown

Who paid Research payments · program years 2023–2025

Merck Sharp & Dohme Corporation $363,261 8 payments
E.R. Squibb & Sons, L.L.C. $15 1 payment

Studies the money was for Research payments · program years 2023–2025

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $288,241 6 payments
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $65,911 1 payment
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $9,108 1 payment
MAD in Patients/Phase 1B (Lupus) - A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants with Discoid Lupus $15 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.